Currently, various tyrosine kinase inhibitors including small molecular antineoplastic drugs and monoclonal antibodies targeting EGFR, HER2, VEGFR, and c‐Met pathways have been developed and tested in human ESCC treatment.7 Here, EGFR is linked to esophageal squamous cell carcinoma.